Oncology division

Quote




Ok, I am in Oncology here and everything I see is, Eisai seems to be taking a break from anything new coming. If there is anything new it's Lenvima + Keytruda which may not pan out. I think one or two things could happen;
1- If it goes well, Merck will take over and let US employees go
2-Doesn't work out and we are reduced
Already they are giving RCC to sleeve 3 OSSs so that shows not much is coming soon.
 




anonymous said:
Ok, I am in Oncology here and everything I see is, Eisai seems to be taking a break from anything new coming. If there is anything new it's Lenvima + Keytruda which may not pan out. I think one or two things could happen;
1- If it goes well, Merck will take over and let US employees go
2-Doesn't work out and we are reduced
Already they are giving RCC to sleeve 3 OSSs so that shows not much is coming soon.
Click to expand...


Japanese companies are almost impossible to acquire…so that’s not happening.
 








I disagree. How does Merck have 51% rights in US? I think Japan would let Merck run all sales of Lenvima in the US and let us go. They would still make money but, have very few people to manage.
 








Just accepted a new position, wow it feels good to be going to a real oncology company. I will miss some of the people but they are all looking too. No pipeline so please be careful!!!
 












anonymous said:
I disagree. How does Merck have 51% rights in US? I think Japan would let Merck run all sales of Lenvima in the US and let us go. They would still make money but, have very few people to manage.
Click to expand...


Not a corporate finance person I see. That is a royalty agreement. Merck does not own 51% of Eisai Co. LTD. Japanese governance makes it near impossible for Japanese owned companies to be acquired by non Japanese companies. So Eisai is not getting bought out. It’s why real oncology people don’t work here. There is no equity upside here like the biotech world where reps can become multi millionaires from buyouts.
 








anonymous said:
Not a corporate finance person I see. That is a royalty agreement. Merck does not own 51% of Eisai Co. LTD. Japanese governance makes it near impossible for Japanese owned companies to be acquired by non Japanese companies. So Eisai is not getting bought out. It’s why real oncology people don’t work here. There is no equity upside here like the biotech world where reps can become multi millionaires from buyouts.
Click to expand...
I disagree, people don't work here because it is run like a primary care job. I'm in the south region and everyone is looking to leave. I hear the same thing is going on in the west. Both RBLs are in over their heads and do not know how to manage but, they think they do, just ask them.
 




anonymous said:
I disagree, people don't work here because it is run like a primary care job. I'm in the south region and everyone is looking to leave. I hear the same thing is going on in the west. Both RBLs are in over their heads and do not know how to manage but, they think they do, just ask them.
Click to expand...


What are you disagreeing about?
 












Wonder who will be the New ABL in the South? I hope it is someone that will listen and understands oncology is not primary care. Too bad we lost so many good people waiting for this too.
 




anonymous said:
Wonder who will be the New ABL in the South? I hope it is someone that will listen and understands oncology is not primary care. Too bad we lost so many good people waiting for this too.
Click to expand...

Good people? Understands oncology? You are at Eisai. Neither of those two things have ever existed…or ever will.

This is a place to run from…not run to.
 
















Top Bottom
Back
Quote